Donald Hooker
Stock Analyst at Keybanc
(2.51)
# 2,319
Out of 5,241 analysts
81
Total ratings
55.95%
Success rate
9.22%
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $6.36 | +1,472.33% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $150.85 | +158.53% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $186.61 | -8.90% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $169.12 | +71.48% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $8.77 | +732.38% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $2.93 | +1,128.67% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $7.57 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $158.86 | +122.21% | 2 | Feb 17, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $82.17 | - | 11 | Dec 2, 2020 | |
| MMS Maximus | Maintains: Overweight | $80 → $84 | $59.36 | +41.51% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $3.96 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $250.40 | -32.11% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $116.38 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $0.82 | +5,509.76% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $415.27 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $6.36
Upside: +1,472.33%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $150.85
Upside: +158.53%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $186.61
Upside: -8.90%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $169.12
Upside: +71.48%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $8.77
Upside: +732.38%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $2.93
Upside: +1,128.67%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $7.57
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $158.86
Upside: +122.21%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $82.17
Upside: -
Maximus
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $59.36
Upside: +41.51%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $3.96
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $250.40
Upside: -32.11%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $116.38
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $0.82
Upside: +5,509.76%
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $415.27
Upside: -